Human heparin cofactor II is a plasma protein that is known to inhibit thrombin. We have recently determined that the reactive-site sequence (P1-P'l) in heparin cofactor II is Leu-Ser (9). Therefore, the reactive-site sequence in heparin cofactor II resembles that found in a1-antichymotrypsin (10) but not that in antithrombin III, which is Arg-Ser (11). Chymotrypsin Aa has a substrate specificity primarily directed toward P1 amino acid residues that have large or aromatic hydrophobic side chains (12). The present investigation was undertaken to determine whether or not heparin cofactor II inhibits chymotrypsin and if the reaction rate is enhanced by glycosaminoglycans. We report here that heparin cofactor II inhibits chymotrypsin more rapidly than thrombin, but the reaction rate is not affected by glycosaminoglycans.
There are numerous proteinase inhibitors in normal human plasma that have essential roles during coagulation, fibrinolysis, and inflammation: a1-proteinase inhibitor, antithrombin III, a1-antichymotrypsin, Ci inhibitor (inhibitor of the activated form of the first component of complement), a2-plasmin inhibitor, and a2-macroglobulin (1) . Heparin cofactor II, described in 1974 by Briginshaw and Shanberge (2, 3) and recently purified by Tollefsen et al. (4) , is a glycoprotein (Mr = 65,600) that functionally resembles antithrombin III in the ability to inhibit thrombin at an accelerated rate in the presence of heparin. Heparin cofactor II is immunologically distinct from antithrombin III and other inhibitors (4-7); thus, it can be included with the plasma proteinase inhibitors listed above. Although heparin cofactor II has some structural and functional properties similar to antithrombin III, the inhibitor exhibits a remarkable specificity for thrombin (2) (3) (4) (5) (6) (7) . Trypsin and other trypsin-like proteinases, including factor Xa, factor IXa, and plasmin, with a P1 substrate specificity for arginyl or lysyl side chains [according to the nomenclature of Schechter and Berger (8) ], are not inhibited by heparin cofactor II (2-7).
We have recently determined that the reactive-site sequence (P1-P'l) in heparin cofactor II is Leu-Ser (9) . Therefore, the reactive-site sequence in heparin cofactor II resembles that found in a1-antichymotrypsin (10) but not that in antithrombin III, which is Arg-Ser (11) . Chymotrypsin Aa has a substrate specificity primarily directed toward P1 amino acid residues that have large or aromatic hydrophobic side chains (12) . The present investigation was undertaken to determine whether or not heparin cofactor II inhibits chymotrypsin and if the reaction rate is enhanced by glycosaminoglycans. We report here that heparin cofactor II inhibits chymotrypsin more rapidly than thrombin, but the reaction rate is not affected by glycosaminoglycans.
EXPERIMENTAL PROCEDURES
Materials. Human plasma heparin cofactor II was isolated as described (13) . Chymotrypsin Aa, heparin (ammonium salt), dermatan sulfate, and succinyl-Ala-Ala-Pro-Phe-p-nitroanilide were obtained from Sigma. Nutritional Biochemicals supplied N-acetyl-a-azaphenylalanine p-nitrophenyl ester; Polybrene and 2,3-butanedione were purchased from Aldrich. All buffers used in this study contained 0.1% (wt/vol) polyethylene glycol (Mr = 8000) to limit protein adsorption to various surfaces.
Enzyme and Inhibitor Assays. Chymotrypsin activity was measured by using succinyl-Ala-Ala-Pro-Phe-p-nitroanilide (14) . Heparin cofactor II activity was determined by measuring the rate of chymotrypsin inhibition in the absence and presence of heparin or dermatan sulfate. Stock chymotrypsin solutions (100 AM) were dissolved in 1 mM HCl and kept at 4°C. Inhibition reactions were started by adding chymotrypsin (final concentration, -15-35 nM) to a solution containing heparin cofactor II (final concentration, about 0.05-2 ,uM) in 50 mM triethanolamine acetate, pH 8.0/100 mM NaCl. Portions (0.1 ml) were removed at intervals, added to a substrate solution (0.8 ml) containing 100 AM succinyl-AlaAla-Pro-Phe-p-nitroanilide in 50 mM triethanolamine acetate, pH 8.0/100 mM NaCl, and incubated at ambient temperature. Polybrene (0.5 mg/ml) was included in the substrate solution when inhibition assays were performed in the presence of heparin or dermatan sulfate. Substrate hydrolysis was terminated after a suitable time, usually 3-5 min, by the addition of glacial acetic acid (0.1 ml). pNitroaniline released during the assay was measured at 400 nm and the amount of substrate hydrolyzed was proportional to the chymotrypsin concentration. Antithrombin activity of heparin cofactor II was determined as described (13, 15) .
Under the reaction conditions used in which heparin cofactor II concentration was in excess of the chymotrypsin concentration, apparent pseudo-first-order kinetics was followed. Under these circumstances, the rate of disappearance of free chymotrypsin (E) may be described by ln(E/Eo) = -k2(IO) t, [11 where the residual activity (%) is E/Eo at time t, I0 is the initial concentration of heparin cofactor II, and k2 is the secondorder rate constant value for reaction of chymotrypsin with the inhibitor. Apparent pseudo-first-order rate constant values (kobJ) can be obtained from the slope of ln(E/E0) against t plots by using various heparin cofactor II concentrations.
The kinetic data for chymotrypsin inhibition by heparin cofactor II were analyzed by the procedure of Kitz and
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Proc. Natl. Acad. Sci. USA 82 (1985) Wilson (16) . The reaction scheme is expressed by KI k3 IO + E¢i± E-+I-E, [2] where IPE represents a reversible inhibitor-enzyme complex that is subsequently stabilized, possibly by bond formation, to I-E. When Io>> E, a double reciprocal plot of kobs values against heparin cofactor II concentration gives 1/kobs = (KI/k3)'(1I/o) + l/k3. [3] The second-order rate constant value for inactivation of chymotrypsin is obtained from the slope and is equivalent to k3/KI, and K1 and k3 values are derived from the x and y intercepts, respectively (16 (20) . Samples were treated at 100°C for 3 min in 1% NaDodSO4. Standards for the calibration of gels were obtained from Bio-Rad (high molecular weight protein kit).
Other Determinations. Protein concentration was determined by using a specific absorption coefficient value of 0.915 ml mg-l cm-1 at 280 nm (13) for human heparin cofactor II and a Mr = 65,600 (4). Chymotrypsin (Mr = 25,000) concentrations were determined at 280 nm with a value of 2.05 mlmg-1cm-1 (12) . Active site titration of chymotrypsin was measured with N-acetyl-a-azaphenylalanine p-nitrophenyl ester as the substrate (21) following the procedure of Gupton et al. (22) . Spectrophotometric measurements were performed with a Hewlett Packard 8451A spectrophotometer. Arginine-modified heparin cofactor II was prepared by using 10 mM 2,3-butanedione in 50 mM sodium borate (pH 8.0) for 30 min in the dark at 300C (23) .
RESULTS
Properties of Chymotrypsin Inhibition. Incubation of chymotrypsin with heparin cofactor II at pH 8.0 and 250C resulted in a time-dependent loss of proteinase activity that followed a first-order process. The semilogarithmic plots of residual chymotrypsin activity against time at various inhibitor concentrations were linear to about 10-15% residual activity (Fig. LA) (Fig. 1B) . by HPLC revealed the elution of one major peak (designated peptide 2) and three minor peaks (designated peptides 1, 3, and 4) (Fig. 2) . Peptide 2 was further analyzed by aminoterminal sequencing, and through eight cycles it had the sequence of Ser-Thr-Gln-Val-Arg-Phe-Thr-Val ... . This is the same sequence obtained by thrombin cleavage of heparin cofactor II and corresponds to the carboxyl-terminal peptide (36 residues) of the protein (13) . Peptides 3 and 4 were found to correspond to residual heparin cofactor II and undissociated complex. Sequence data for peptide 1 were not determined. The extremely small peaks shown in the chromatogram from approximately 40 Interaction of Heparin Cofactor II with Chymotrypsin. Evidence for a similar cleavage site (reactive-site bond) in heparin cofactor II between chymotrypsin and thrombin was examined. We previously determined the primary sequence of the reactive-site peptide, beginning with the P'1 residue, released from the inhibitor-thrombin complex and purified by reverse-phase HPLC (13) .
Analysis of the heparin cofactor 1I-chymotrypsin complex Table 1 . Thrombin and chymotrypsin react with the same site on heparin cofactor II and both appear to form 1:1 molar complexes with the inhibitor. Therefore, heparin cofactor II is a "singleheaded" proteinase inhibitor (at least with respect to thrombin and chymotrypsin) as opposed to "multi-headed" as has been described for other proteinase inhibitors (29) .
Hunt and Dayhoff (30) proposed a new protein superfamily consisting of ovalbumin (31) , antithrombin III (32) (33) (34) , and a1-proteinase inhibitor (35, 36) (Fig. 3) . a1-Antichymotrypsin (10, 37), angiotensinogen (38) , and heparin cofactor II (13) (10, 37) , and heparin cofactor II (full sequence not known) (present study; refs. 9, 13). The reactive-site residues (Pl-P'l) are enclosed in the box.
Proc. Natl. Acad. Sci. USA 82 (1985) sequence homology in the reactive-site peptide region (Fig.  3) . However, unlike heparin cofactor II, a1-antichymotrypsin, which inhibits chymotrypsin-like proteinases, is not reactive toward any trypsin-like enzymes (1) . Although the three-dimensional structure is not known, the results of the present investigation imply that the reactive-center region in heparin cofactor II is able to recognize both thrombin and chymotrypsin.
Thrombin inhibition by heparin cofactor II is very rapid in the presence of heparin or dermatan sulfate with secondorder rate constant values approaching ca. 108 M-1 min'- (4, 6, 13, 39, 40) . Interestingly, there is no apparent enhancement of the rate of chymotrypsin inhibition by heparin cofactor II including these glycosaminoglycans. This may be due to the inability of chymotrypsin to bind heparin, as does thrombin, to form a ternary proteinase-heparin-inhibitor complex (40) .
Although it appears that an in vivo role can be proposed for thrombin inhibition by heparin cofactor 11 (4, 6, 13, 39, 40) , an additional role related to chymotrypsin-like proteinase inhibition might also be possible. There are numerous chymotrypsin-like proteinases suggested to have a physiological role in protein turnover and in tissue-localized angiotensin II formation: peritoneal mast cell proteinase I (41), skeletal muscle mast cell proteinase 11 (42) , cytoplasmic mast cell chymase (43) , salivary gland tonin (44, 45) , skin chymotrypsin-like proteinase (45, 46) , and neutrophil cathepsin G (28, (45) (46) (47) (48) .* Although there are differences in the structural, functional, and catalytic activities of these chymotrypsin-like enzymes compared to chymotrypsin (41) (42) (43) (44) (45) (46) (47) (48) , one of these proteinases may be inhibited by heparin cofactor II (with or without glycosaminoglycan) at a physiologically important rate. 
